The Targeted Delivery Interest Group (TDIG) is a NIH multi-institutional team that champions targeted delivery of therapeutics to different organs for selective and effective treatments with reduced harmful effects. The group aims to identify gaps and opportunities to advance basic, translational, and clinical research for multiple delivery platforms applicable for the treatment of multiple diseases including autoimmunity, transplantation, cancers, neurodegeneration, cardiovascular diseases, and infectious diseases.
TDIG Monthly Webinar Series
This Month's Webinar
Date and Time: September 22, 2023 at 12:00 p.m. EST
Presenter: Adam Margolin, Ph.D., CEO, Flashpoint Therapeutics
The TDIG monthly webinar series will facilitate ideas exchanges and collaborations among academia, pharma, government, and the regulatory communities.
See the webinar schedule and information about past webinars.
TDIG Monthly Webinar Series is open to all.
Related Funding
Request for Information (RFI) issued by the Office of Strategic Coordination
This Notice is a time-sensitive RFI inviting comments and guidance to be considered during the development of a prize competition to advance delivery technologies that fully realize the promise of somatic genome editing to reduce disease burden.
Contact Information
For suggestions, please contact the TDIG committee members: